Chemotherapy with gemcitabine‐containing regimens...

Chemotherapy with gemcitabine‐containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma

Abstract

AbstractBACKGROUNDResults from Phase II trials conducted in Asia have shown that gemcitabine alone (GEM) or with cisplatin (GC) is active among patients with metastatic or locally recurrent nasopharyngeal carcinoma (NPC).METHODSAt the Princess Margaret Hospital (PMH), Toronto, 32 patients with NPC were treated with GEM (n = 18) or GC (n = 14) from January 2000 to October 2001. Patients either received 1000 mg/m2 GEM on Days 1, 8, and 15 every 28 days as a single agent, or with cisplatin (CG) given on day 2 at 70 mg/m2.RESULTSMost patients (91%) were of Southeast Asian ancestry and 29 (91%) had Type 2 (World Health Organization 1991 classification) nonkeratinizing histology. Sixteen of the GEM (89%) and five (36%) of the GC patients had received chemotherapy before entering the study. Median follow‐up was 32 weeks (range, 2–97 weeks) for both groups. In the GEM group, there were five (28%) partial responses (PR) and one (6%) complete response (CR), giving an overall response rate of 34% (95% confidence interval [CI], 13.59). In the GC group, there were two (14%) CRs and seven PRs (50%), giving an overall response of 64% (95% CI, 35–87). Hematologic toxicity was dose limiting but uncomplicated. Nonhematologic toxicity included one patient with reversible reactivation of hepatitis, one with Grade 3 cisplatin‐related sensory neuropathy, and three with cardiovascular events that were possibly related to chemotherapy. The median duration of response for the GEM and GC patients was 17 and 24 weeks and the 1‐year survival rate was 48% (95% CI, 18–78) and 69% (95% CI, 40–99), respectively. Median survival has not been reached.CONCLUSIONSOur study confirms that GEM is an active and tolerable drug for patients with NPC. Cancer 2002;95:2516–23. © 2002 American Cancer Society.DOI 10.1002/cncr.10995

Authors

Ma BBY; Tannock IF; Pond GR; Edmonds MR; Siu LL

Journal

Cancer, Vol. 95, No. 12, pp. 2516–2523

Publisher

Wiley

Publication Date

December 15, 2002

DOI

10.1002/cncr.10995

ISSN

0008-543X

Associated Experts

Gregory Pond

Professor, Faculty of Health Sciences

Visit profile

Labels